HONG KONG – A coronavirus vaccine trade could emerge in Asia’s capital markets in 2021 with dealmakers confident the record-breaking pace of raisings in the past year should be maintained in the new year.
Equity capital markets (ECM) deals in the Asia-Pacific region, including Japan, totalled US$439.1 billion in 2020, the highest ever, which accounted for 41 per cent of the world’s total of US$1.06 trillion according to Refinitiv data.
The contribution by the Asian region to the global total value of capital raisings was the most since 2010 which advisers attributed to some countries, led by China, emerging from the pandemic faster than the rest of the world.
In Asia, healthcare deals recorded the strongest growth in the past year, up 148.6 per cent in terms of money raised, and bankers believe the global roll out of the coronavirus vaccine will see the sector dominate the local capitals market again in 2021.
“There is a window of opportunity for Covid-related trades to raise money in 2021,” said Selina Cheung, managing director of Asia ECM origination at UBS in Hong Kong.
“We expect to see more health-related and vaccine companies coming to the market in the first half.”
The pace of capital market activity throughout the year surprised dealmakers who had expected reduced activity until unprecedented liquidity from governments and central banks began flooding the global system.
Almost US$7.5 trillion has been spent by global central banks in 2020 to cushion the economic impacts created by coronavirus, according to the IMF’s (International Monetary Fund) annual report published in November.
“A lot of people did not expect this level of activity in the market but it’s been very welcome and it’s been a good boost to the economy as it has injected a lot of capital that has been needed,” said Kenneth Ho, managing director of ECM at Haitong International.
“The market is driven by liquidity and it should remain in place for a while to come.”
Hong Kong will finish 2020 as the world’s second most popular IPO (initial public offering) venue behind the Nasdaq with 119 deals worth US$31.21 billion, the Refinitiv data showed.
“We see a sizeable pool of companies that have reached a certain scale in their business where they are ready to become public, and we expect investors in 2021 will continue to be open to looking at such companies across different sectors,” Credit Suisse’s head of ECM for Asia-Pacific, Johnson Chui, said in regard to Hong Kong’s IPO prospects.
The US$37 billion Ant Group IPO, shelved in November when China announced a new regulatory regime for fintech companies, would have propelled Hong Kong to the top of the global rankings.
Mega deals like Kuaishou Technology, which could raise up to US$5 billion, and JD Logistics which is aiming to raise up to US$2 billion, according to Reuters reports, are being closed watched for the first half of the new year.
Bankers are also on the lookout for an IPO from Didi Chuxing, which is considering a Hong Kong IPO in 2021 that would value it at up to US$60 billion, according to sources.